Kailera Therapeutics, Inc. Common Stock (KLRA) Stock
Key stats
- Market cap
- $1.87B
- Price / Earnings ratio
- -12.4x
- EPS (TTM)
- -$949.00
- Volume
- Loading
- 52-week high
- $28.23
- 52-week low
- $9.76
Source: third-party data provider, as of November 13, 2026
Compare with KLRA
Recent news

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
KLRA

Kailera's GLP-1 drug meets main goal of late-stage trials
Kailera's GLP-1 drug meets main goal of late-stage trials
KLRA

Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
KLRA

Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up
Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up
KLRA
Technical indicators
- RSI 14
- 62.15
- MACD 12/26/9
- 0.34
- EMA 9 of MACD
- 0.11
- MACD histogram
- 0.22
- SMA 50
- $12.66
- Price above SMA 50
- EMA 50
- $13.43
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
KLRA

Kailera's GLP-1 drug meets main goal of late-stage trials
Kailera's GLP-1 drug meets main goal of late-stage trials
KLRA

Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
KLRA

Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up
Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up
KLRA

Kailera Therapeutics files for US IPO
Kailera Therapeutics files for US IPO
KLRA
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald C. Renaud Jr., M.B.A. | President, CEO & Director | 1969 |
| Mr. Douglas W. Pagan M.B.A. | Chief Financial Officer | 1972 |
| Mr. Paul Douglas Burgess J.D., M.S. | Chief Operating & Business Officer | 1974 |
| Ms. Jamie Beth Coleman | Chief Commercial Officer | 1978 |
| Maura Gavaghan | Vice President of Corporate Communications & Investor Relations | — |
| Mr. Scott M. Akamine J.D. | Chief Legal Officer & Secretary | 1985 |
| Ms. Paula A. Cloghessy SHRM-SCP, SPHR | Chief People Officer | 1972 |
| Dr. Scott M. Wasserman M.D. | Chief Medical Officer | 1970 |
| Ms. Kathleen Tregoning M.A. | Chief Corporate Affairs Officer | 1971 |
| Mr. Corey Manchester | Treasurer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 62.15
- MACD 12/26/9
- 0.34
- EMA 9 of MACD
- 0.11
- MACD histogram
- 0.22
- SMA 50
- $12.66
- Price above SMA 50
- EMA 50
- $13.43
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $44.00
- Average
- $44.00
- High
- $44.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.8 | -8.8 | -5.0 | -18.6 | -11.1 | -30.4 | +16.6 | +18.4 |



